Fluorouracil

Introduction Overview

Generic Name

Fluorouracil

Brand Name

Adrucil

Dosage Form

Injection for intravenous use

Drug Class

Antineoplastic Agents, Antimetabolites

Pharmacokinetics

Absorption:
Fluorouracil (5-FU) is administered parenterally, primarily via intravenous injection or continuous infusion, as it has poor and inconsistent gastrointestinal absorption when given orally. This administration route ensures complete bioavailability and rapid systemic distribution. The drug's prompt entry into systemic circulation results in near-immediate availability at target sites. The lack of oral absorption necessitates IV use for therapeutic efficacy. Pharmacokinetic parameters demonstrate rapid attainment of peak plasma concentrations following bolus administration, whereas continuous infusion maintains steady-state concentrations for extended cytotoxic effect.

Distribution:
5-FU exhibits extensive tissue distribution, notably concentrating in rapidly proliferating tissues such as intestinal mucosa and bone marrow, which aligns with its cytotoxic activity. It penetrates into the liver, central nervous system compartments including cerebrospinal fluid (CSF), and brain tissue. Tumor tissues often demonstrate higher accumulation of fluorouracil or its metabolites compared to adjacent normal tissues, potentially due to impaired uracil catabolism in malignant cells. This selective retention in tumors suggests partial tumor specificity, which may enhance therapeutic targeting. However, the drug’s distribution into human milk is not well established.

Metabolism:
Fluorouracil undergoes extensive hepatic metabolism, predominantly via enzymatic degradation by dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in its catabolic pathway. The bulk of administered 5-FU is converted into inactive metabolites such as carbon dioxide, urea, alpha-fluoro-beta-alanine, and other fluorinated catabolites. A minor fraction is anabolized intracellularly to active nucleotides, including 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which mediates its cytotoxic effects. Genetic polymorphisms affecting DPD activity can markedly influence metabolism rates, resulting in increased toxicity risk for patients with enzyme deficiency. Research into partial versus complete DPD deficiency impacts dosing recommendations and toxicity management.

Elimination:
Fluorouracil exhibits a short elimination half-life ranging from 8 to 20 minutes post-bolus intravenous injection, which increases with higher doses. Renal excretion accounts for 5-20% of unchanged drug elimination, primarily within 6 hours of administration. Metabolites are primarily excreted via urine within 3 to 4 hours. Hepatic metabolism dominates elimination, underscoring the importance of liver function in clearance. The rapid clearance necessitates either repeated bolus doses or continuous infusion to maintain therapeutic drug levels. The potential accumulation of toxic metabolites in renal impairment remains an area for clinical vigilance. Clinical implications of elimination kinetics guide infusion scheduling and dose adjustments.

Dosage Forms

Available Dosage Forms:
- Injection for intravenous use: 50 mg/mL solution
- Pharmacy bulk packages: 2.5 g and 5 g doses in vials intended for individual dose preparation, not for direct infusion

Dosages for Adults and Adolescents:
- Colorectal Cancer: Various regimens including fluorouracil with leucovorin or levoleucovorin:
- Direct IV injection: 500 mg/m2 on specified days within an 8-week cycle
- Continuous IV infusion: 400 mg/m2 IV bolus followed by 2400–3000 mg/m2 over 46 hours every 14 days
- Combination regimens such as FOLFOX, FOLFIRI, and FOLFOXIRI with specified dosing schedules and infusion durations
- Mayo Clinic regimen (monthly): daily doses for 5 consecutive days, followed by rest intervals
- Roswell Park regimen (weekly): leucovorin over 2 hours followed by fluorouracil injection weekly for 6 weeks, repeated in cycles
- Modified deGramont regimen (bimonthly): leucovorin infusion and fluorouracil continuous infusion over 2 days, repeated every 2 weeks
- Breast Cancer: Combination regimens with cyclophosphamide and methotrexate:
- Fluorouracil 500–600 mg/m2 IV on days 1 and 8 every 28 days
- CMF regimen: fluorouracil 600 mg/m2 IV with oral cyclophosphamide and IV methotrexate, repeated monthly
- Gastric and Pancreatic Cancer:
- Continuous IV infusion doses vary between 200–1000 mg/m2 in combination with platinum-based or other regimens

Specific Patient Populations:
- Geriatric Patients: Dose reductions for patients over 60 years, particularly in breast cancer combination therapy (e.g., fluorouracil reduced to 400 mg/m2 and methotrexate to 30 mg/m2)
- Dosage individualization is emphasized based on tumor type, clinical response, comorbidities, and toxicity
- Dose adjustments are required based on toxicity grades, with specific protocols for withholding and resuming therapy

Administration Considerations:
- Administered intravenously using established IV lines or central venous catheters, sometimes via regional infusions for specific tumor targeting
- Avoid extravasation to prevent local tissue damage
- Infusion schedules and dosing require careful adherence to clinical regimen protocols to optimize efficacy and reduce toxicity

Mechanism Of Action

Fluorouracil (5-FU) exerts its antineoplastic effects primarily as a pyrimidine antimetabolite interfering with nucleic acid metabolism. Its principal mechanism involves the inhibition of thymidylate synthase (TS), a key enzyme responsible for the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), essential for DNA synthesis and repair. The active metabolite, 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), forms a stable, covalent ternary complex with TS and the reduced folate cofactor N5,10-methylenetetrahydrofolate, effectively preventing the synthesis of thymidylic acid. This results in thymidine nucleotide depletion, leading to DNA damage and apoptosis in rapidly proliferating tumor cells.

In addition to DNA synthesis inhibition, fluorouracil metabolites also disrupt RNA processes. For example, fluorouridine triphosphate (FUTP) is incorporated into RNA in place of uridine triphosphate (UTP), resulting in defective RNA processing and impaired protein synthesis. This misincorporation leads to altered RNA function, interference with RNA splicing, and disruption of translational processes which contributes to cytotoxicity.

The dual action on DNA and RNA, complemented by folate potentiation (e.g., co-administration of leucovorin or levoleucovorin), enhances the cytotoxic effect selectively towards tumor cells. This potentiation is due to increased intracellular folate pools, which augment the stability and binding of the FdUMP-TS complex. Clinical studies have demonstrated improved response rates and survival in colorectal and other gastrointestinal cancers when fluorouracil is combined with folate agents.

Comparatively, fluorouracil differs mechanistically from other antimetabolites like methotrexate, which inhibit dihydrofolate reductase, and cytarabine, a nucleoside analog causing DNA chain termination. Fluorouracil's ability to affect both DNA and RNA pathways provides a broader anti-tumor mechanism. Ongoing research continues to unravel the full molecular pathways involved, including effects on cell cycle regulation and apoptosis induction, supporting its sustained role in chemotherapy regimens.

Pharmacological Actions

Antimetabolite activity through inhibition of DNA synthesis via thymidylate synthase blockade
Incorporation into RNA disrupting RNA processing and protein synthesis
Induction of cell cycle arrest and apoptosis in rapidly proliferating tumor cells
Selective cytotoxicity enhanced in cells with high proliferation rates such as tumors
Potentiated cytotoxic activity when combined with folate analogs like leucovorin
Modulation of antineoplastic activity based on dihydropyrimidine dehydrogenase enzyme activity
Ability to be administered as bolus injection or prolonged continuous infusion for tailored antitumor activity
Metabolism primarily via hepatic enzymatic degradation limiting systemic toxicity
Demonstrated efficacy in multiple solid tumor types including colorectal, breast, gastric, and pancreatic cancers
Potential for accumulation of toxic metabolites in patients with impaired metabolic capacity
Capability for combination use with other cytotoxic agents enhancing therapeutic effect
Exhibit dose-dependent pharmacokinetics with short plasma half-life
Induction of immune-modulatory effects possibly through tumor cell apoptosis

Therapeutic Or Clinical Uses

Treatment of adenocarcinomas of the colon and rectum, including metastatic and adjuvant settings
Adjunct therapy post-surgery for solid tumors such as colorectal carcinoma
Component of standard chemotherapy regimens for advanced colorectal cancer, including FOLFOX, FOLFIRI, and FOLFOXIRI
Treatment of breast cancer, both metastatic and as adjuvant therapy in combination with agents like cyclophosphamide and methotrexate
Used in certain protocols for gastric and pancreatic cancers, often in combination with platinum-based drugs
Off-label use in esophageal cancer either as monotherapy or combined with cisplatin
Combination chemotherapy for head and neck squamous cell carcinoma, including use with radiation therapy for unresectable disease
Concurrent chemoradiotherapy with cisplatin for invasive cervical cancer
Treatment regimens for metastatic renal cell carcinoma and carcinoid tumors (off-label usage)
Second-line therapy in ovarian epithelial carcinoma, including platinum-refractory disease
Usage in liver cancers such as hepatoblastoma as part of multi-agent regimens
Regional administration via hepatic artery infusion for liver metastases (off-label, under investigation)
Palliative treatment protocols in advanced malignancies where curative options are limited
Combination with leucovorin or levoleucovorin to improve therapeutic efficacy
Option in limited-resource settings where doublet regimens may not be feasible

Side Or Adverse Effects

Gastrointestinal toxicity including severe diarrhea, mucositis, stomatitis, esophagopharyngitis, and nausea
Myelosuppression presenting as neutropenia, thrombocytopenia, and anemia, sometimes severe or fatal
Palmar-plantar erythrodysesthesia (hand-foot syndrome) characterized by erythema, pain, swelling, and desquamation
Alopecia and dermatologic reactions such as pruritic maculopapular rash
Cardiotoxic effects including myocardial ischemia, angina (including variant angina), arrhythmias, heart failure, and myocardial infarction
Neurologic effects such as disorientation, confusion, ataxia, visual disturbances, acute cerebellar syndrome, and hyperammonemic encephalopathy
Potential for fatal toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency
Risk of infection secondary to immunosuppression from leukopenia
Fetal harm and teratogenicity when used during pregnancy
Impairment of male and female fertility as suggested from animal studies
Injection site reactions and risk of tissue damage with extravasation
Fatigue and general malaise associated with chemotherapy
Electrolyte imbalances due to severe diarrhea requiring fluid and electrolyte management
Possible neurotoxic effects manifesting with altered mental status
Secondary malignancies or long-term sequelae related to immunosuppression and cytotoxicity

Precautions

Screen for dihydropyrimidine dehydrogenase (DPD) deficiency prior to initiation due to risk of severe toxicity
Monitor for signs of cardiotoxicity, especially in patients with preexisting coronary artery disease
Close observation for neurologic symptoms, with therapy interruption if cognitive or motor disturbances occur
Frequent monitoring of complete blood counts during therapy to detect myelosuppression
Maintain vigilance for severe gastrointestinal adverse effects requiring treatment interruption and supportive care
Use extreme caution when combined with leucovorin or levoleucovorin due to potentiation of toxicity
Inform women of childbearing potential and male patients with partners susceptible to pregnancy regarding contraception use during and after therapy
Avoid breastfeeding during treatment due to unknown excretion into human milk
Adjust doses in elderly patients, especially over 60 years, to reduce risk of toxicity
Ensure adequate hydration and manage electrolyte disturbances promptly
Educate patients to report hand-foot syndrome symptoms early for intervention
Interrupt therapy for grade 3 or 4 diarrhea, mucositis, or significant myelosuppression until resolution
Temporarily discontinue drug if cardiotoxicity or neurologic toxicities are identified until medically evaluated
Consider dose modifications guided by tolerance and clinical response rather than arbitrary reductions
Evaluate renal and hepatic function periodically as these may impact metabolism and elimination

Warnings

Severe, life-threatening, or fatal toxicity may occur in patients with complete or near-complete DPD deficiency
Cardiotoxicity may manifest as ischemia, arrhythmia, heart failure, or angina – continuous monitoring warranted
Neurologic toxicity including acute cerebellar syndrome and hyperammonemic encephalopathy reported with serious clinical consequences
Risk of severe GI toxicity including mucositis and diarrhea can lead to rapid deterioration if untreated
Hand-foot syndrome can be dose-limiting and requires prompt recognition and management
Myelosuppression may be severe and lead to infection or bleeding complications; requires routine hematologic assessment
Therapy should be permanently discontinued in patients with severe early onset toxicity due to metabolic deficiency
Safety of drug resumption following cardiotoxic or neurologic adverse events remains unestablished
Potential teratogenicity necessitates avoidance of drug during pregnancy; unintended exposure should prompt counseling
Avoid unmonitored combination with folate agents in debilitated or elderly patients due to increased serious toxicity risk
Extravasation of IV administration can cause severe tissue injury
Caution in use for patients with concomitant illnesses that may exacerbate toxicity profile
Observe for drug interactions that can potentiate bleeding risk or alter metabolism
Monitor closely in prolonged or continuous infusion regimens due to accumulation potential
Maintain clinical vigilance during dose adjustments to balance efficacy against toxicity

Contraindication

No absolute contraindications formally stated by manufacturer
Use with caution or avoid in patients with known DPD deficiency due to fatal toxicity risk
Hypersensitivity to fluorouracil or any component of the formulation
Patients with severe bone marrow suppression unrelated to cancer therapy
Severe hepatic impairment owing to metabolism concerns
Pregnancy due to high risk of fetal toxicity (pregnancy category D)
Lactation period due to unknown excretion in breast milk
Concurrent use with incompatible drugs causing severe adverse interactions
Conditions with active severe infection due to additive immunosuppressive effects
Severe cardiac disease without close monitoring due to potential cardiotoxicity

Drug Interactions

Coumarin anticoagulants (e.g., warfarin): fluorouracil or metabolites may inhibit CYP2C9, increasing anticoagulation effect; monitor INR/PT closely and adjust doses accordingly
Leucovorin or levoleucovorin: potentiates fluorouracil cytotoxicity and toxicity, used therapeutically but requires careful monitoring especially in elderly or debilitated patients
CYP2C9 substrates may have altered metabolism due to fluorouracil-mediated enzyme inhibition
Incompatible drugs for IV admixture include: carboplatin, ciprofloxacin, cisplatin, cytarabine, diazepam, doxorubicin, epirubicin, fentanyl, leucovorin calcium, levoleucovorin calcium, metoclopramide, and morphine sulfate
Compatible co-administration with drugs like bleomycin, cyclophosphamide, etoposide, methotrexate, vincristine sodium, and others facilitates multi-drug chemotherapy regimens
Potential additive myelosuppression and GI toxicity when combined with other cytotoxic agents
Drugs affecting renal or hepatic function may alter fluorouracil clearance and toxicity profile
Possible interactions with medications influencing cardiac conduction or function may exacerbate cardiotoxicity
Use caution with agents inducing or inhibiting enzymes involved in fluorouracil metabolism
Certain antiemetics or supportive care drugs (e.g., ondansetron) exhibit variable compatibility requiring attention to administration protocols
Avoid concurrent use with drugs causing severe immunosuppression without appropriate monitoring
Fluorouracil may increase plasma concentration of other drugs metabolized by CYP2C9
Administration with leucovorin or levoleucovorin improves clinical efficacy but drastically increases toxicity potential
Concurrent use with radiation therapy may have additive toxicities necessitating dose adjustments
Potential pharmacodynamic interactions increasing risk of skin toxicity or neurotoxicity

Preparations Of The Drug

Fluorouracil Injection, for intravenous use, 50 mg/mL concentration in single-use vial
Pharmacy bulk packages containing 2.5 g or 5 g of fluorouracil powder for reconstitution (e.g., Adrucil by Teva)
Formulations intended solely for dose preparation, not for direct intravenous infusion, to be diluted or used in controlled infusion devices
Storage conditions include room temperature (20–25°C), protection from freezing and light
Common excipients as per specific product labeling, potential clinical relevance in sensitive individuals
Handling guidelines consistent with hazardous antineoplastic agents according to ASHP recommendations
Compatibility with various infusion solutions such as amino acids 4.25%, dextrose 5%, sodium chloride 0.9%
Y-site injectable compatibility with multiple other chemotherapeutic and supportive agents, with documented incompatibilities
Products supplied with specific instructions to discard unused portions of bulk packages within 4 hours after vial puncture
Parenteral formulations prone to precipitation especially at low temperatures; proper warming or handling advised
Available under brand and generic names with manufacturer and repackager details varying by region
Preparation for continuous infusion requires sterile technique and use of pumps or controlled infusion devices
Commercial preparations often supplemented by leaflets with dosing, stability, compatibility, and safety information